Information Provided By:
Fly News Breaks for March 15, 2016
KPTI
Mar 15, 2016 | 08:29 EDT
BofA/Analyst analyst Catherine Hu downgraded Karyopharm to Underperform and lowered her price target to $11 from $26. The analyst said STORM interim selinexor data expected mid-year could show a treatment hurdle in safety and tolerability and will also challenge the move to earlier lines of treatment where the potential market opportunity is greater. If selinexor is approved but remains a late-stage therapy, Hu only sees a modest market opportunity.
News For KPTI From the Last 2 Days
There are no results for your query KPTI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.